Key points are not available for this paper at this time.
Population
105 patients with recurrent episodes of PSVT
Design
Extension study
Answers are grounded in this paper and cite their sources.
May support unsupervised etripamil use for recurrent PSVT; extends prior data but leaves open need for randomized confirmation.
=0.0045). Forty-five of 105 patients (42.9%) had ≥1 treatment-emergent adverse event, generally transient and mild-to-moderate, including nasal congestion (14.3%), nasal discomfort (14.3%), or rhinorrhea (12.4%). No serious cardiac safety events were observed within 24 hours of etripamil. Conclusions In this extension study, investigational etripamil nasal spray was well tolerated for self-treating recurrent episodes of PSVT without medical supervision. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT03635996.
No takes yet. Share an insight, caveat, or question.
Ip et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: